Merck gets positive EMA Committee opinion for Keytruda, chemotherapy combo for Resectable non-small cell lung cancer Ruchika Sharma26 Feb 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Merck application for Keytruda plus chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma accepted by USFDA for priority review Ruchika Sharma22 Feb 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
Merck seeks more deals to prepare for Keytruda revenue decline Ruchika Sharma4 Feb 2024 12:30 PM ISTMerck & Co on Thursday said it was in the market for deals of up to around $15 billion as it plans for a loss of revenue from its aging cancer...
EMA validates Type II variation application for Padcev with Keytruda for first line treatment of advanced Bladder Cancer: Pfizer Ruchika Sharma28 Jan 2024 10:00 AM ISTTokyo: Astellas Pharma Inc. and Pfizer Inc. have announced that the European Medicines Agency (EMA) has validated for review a Type II...
Merck gets USFDA nod for Keytruda plus chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical Cancer Ruchika Sharma13 Jan 2024 1:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...
Merck gets European Commission nod for two new indications for Keytruda in gastrointestinal cancers Ruchika Sharma22 Dec 2023 11:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the European Commission (EC) has approved two new indications...
Merck bags USFDA nod for Keytruda, Padcev combo for urothelial cancer Ruchika Sharma18 Dec 2023 1:45 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA,...
Merck announces positive results from phase 2 trial evaluating coformulation of vibostolimab, pembrolizumab in lung cancer patients Ruchika Sharma10 Dec 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced full results from the non-registrational Phase 2 KeyVibe-002...
Merck-Eisai endometrial cancer therapy combo fails first-line treatment trial Ruchika Sharma9 Dec 2023 1:30 PM ISTRahway: Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
Merck application for Keytruda plus Padcev for Urothelial Cancer gets USFDA priority review Ruchika Sharma2 Dec 2023 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Merck gets positive EMA Committee opinion for Keytruda plus Gemcitabine, Cisplatin for Biliary Tract Cancer Ruchika Sharma14 Nov 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the European Medicines Agency's Committee for Medicinal...
